Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study

被引：2
|
作者：
Phan, Alexandria T.
Caplin, Martyn E.
Pavel, Marianne E.
Cwikla, Jaroslaw B.
Raderer, Markus
Sedlackova, Eva
Cadiot, Guillaume
Wolin, Edward M.
Capdevila, Jaume
Wall, Lucy
Rindi, Guido
Langley, Alison
Gomez-Panzani, Edda
Ruszniewski, Philippe B.
机构：
[1] Houston Methodist, Houston, TX USA
[2] Royal Free Hosp, London NW3 2QG, England
[3] Charite, D-13353 Berlin, Germany
[4] Univ Varmia & Masuria, Olsztyn, Poland
[5] Univ Hosp Vienna, Vienna, Austria
[6] First Fac Med, Prague, Czech Republic
[7] Gen Teaching Hosp, Prague, Czech Republic
[8] Hop Robert Debre, Reims, France
[9] Markey Canc Ctr, Lexington, KY USA
[10] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[11] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[12] Univ Cattolica Sacro Cuore, Rome, Italy
[13] Ipsen, Les Ulis, France
[14] Hop Beaujon, Clichy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
233
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
    Phan, A. T.
    Wolin, E. M.
    Fisher, G. A.
    Ruszniewski, P.
    Pavel, M.
    Liyanage, N.
    Mirakhur, B.
    Braun, S.
    Caplin, M.
    Vinik, A., I
    NEUROENDOCRINOLOGY, 2017, 105 : 206 - 206
  • [32] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I
    Shah, T.
    Pape, U. F.
    Thanh, Truong X. M.
    Houchard, A.
    Ruszniewski, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 143 - 143
  • [33] Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
    Núria Buil-Bruna
    María Jesús Garrido
    Marion Dehez
    Amandine Manon
    Thi Xuan Quyen Nguyen
    Edda L. Gomez-Panzani
    Iñaki F. Trocóniz
    Clinical Pharmacokinetics, 2016, 55 : 461 - 473
  • [34] Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
    Buil-Bruna, Nuria
    Jesus Garrido, Maria
    Dehez, Marion
    Manon, Amandine
    Thi Xuan Quyen Nguyen
    Gomez-Panzani, Edda L.
    Troconiz, Inaki F.
    CLINICAL PHARMACOKINETICS, 2016, 55 (04) : 461 - 473
  • [35] Long-Term Efficacy and Safety with Lanreotide Autogel/ Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
    Phan, A. T.
    Pavel, M.
    Caplin, M.
    Wolin, E. M.
    Mirakhur, B.
    Massien, C.
    Liyanage, N.
    Lowenthal, Pittman S.
    Ruszniewski, P.
    NEUROENDOCRINOLOGY, 2017, 105 : 207 - 207
  • [36] Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours
    Wolin, E.
    Caplin, M.
    Pavel, M.
    Cwikla, J.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Capdevila, J.
    Wall, L.
    Rindi, G.
    Langley, A.
    Gomez-Panzani, E.
    Ruszniewski, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S461 - S461
  • [37] QUALITY OF LIFE (QOL) WITH LANREOTIDE DEPOT (LAN) VS PLACEBO IN PATIENTS WITH PANCREATIC AND GASTROINTESTINAL NEUROENDOCRINE TUMOURS: RESULTS FROM THE CLARINET PHASE III STUDY.
    Iwasaki, Michiko
    Phan, Alexandria
    Caplin, Martyn
    Ruszniewski, Philippe
    Pavel, Marianne
    Gomez-Panzani, Edda
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E144 - E144
  • [38] Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I.
    Shah, T.
    Pape, U-F.
    Thanh, X-M. Truong
    Houchard, A.
    Ruszniewski, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S773 - S773
  • [39] Lanreotide Autogel/Depot Shows Antitumor Effects in Patients with Metastatic Enteropancreatic NETs: Results of the Clarinet Extension Study
    Caplin, Martyn E.
    Ruszniewski, Philippe
    Pavel, Marianne Ellen
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiota, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Blumberg, Joelle
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [40] CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen
    Ruszniewski, Philippe
    Cwikla, Jaroslaw
    Lombard-Bohas, Catherine
    Borbath, Ivan
    Shah, Tahir
    Pape, Ulrich -Frank
    Xuan-Mai Truong Thanh
    Houchard, Aude
    Pavel, Marianne
    PANCREAS, 2020, 49 (03) : 484 - 485
12345